Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616614 · ClinicalTrials.gov registry record · Phase 3
Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 862
- Enrollment target
NCT02616614: Completed Phase 3 study, sponsored by Actavis.
NCT02616614 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 862 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02616614, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 862 participants
- Enrollment target
Study Summary
Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
Primary Outcome
Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.
Interventions
- DRUG Placebo
- DRUG Onexton
- DRUG Clindamycin/benzoyl peroxide gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 862 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
What the finished NCT02616614 record still lists
NCT02616614 is an interventional study that assigns participants to a tested intervention. The registered 862 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02616614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02616614 about?
NCT02616614 is a clinical study titled "Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris". Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
What is the current status of trial NCT02616614?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 862 participants. The study started on 2015-05. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02616614?
The interventions under investigation include: Placebo (DRUG), Onexton (DRUG), Clindamycin/benzoyl peroxide gel (DRUG).
Who is sponsoring clinical trial NCT02616614?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02616614's enrollment target sits among peer trials
862 380th of 2000 higher than 1,621 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- NCT06256588 · 864 participants · Phase 3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- NCT06527794 · 864 participants · NA
Remote Hypertension Management for Black Patients
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia